Susquehanna Fundamental Investments, LLC Xenon Pharmaceuticals Inc. Transaction History

Susquehanna Fundamental Investments, LLC

  • $4.33 Trillion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 16, 2023
SELL
$33.46 - $40.35 $677,999 - $817,612
-20,263 Reduced 70.69%
8,400 $300,000
Q4 2022

Feb 14, 2023
SELL
$33.06 - $39.43 $149,365 - $178,144
-4,518 Reduced 13.62%
28,663 $1.13 Million
Q3 2022

Nov 14, 2022
SELL
$30.79 - $39.82 $383,828 - $496,396
-12,466 Reduced 27.31%
33,181 $1.2 Million
Q1 2022

May 16, 2022
BUY
$25.09 - $33.13 $621,755 - $820,994
24,781 Added 118.76%
45,647 $1.4 Million
Q3 2021

Nov 15, 2021
BUY
$14.86 - $19.45 $310,068 - $405,843
20,866 New
20,866 $319,000

Others Institutions Holding XENE

# of Institutions
212
Shares Held
70.2M
Call Options Held
88.3K
Put Options Held
28.8K
View Full List

About Xenon Pharmaceuticals Inc.

XENE Quotes by TradingView
  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.42B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Susquehanna Fundamental Investments, LLC Portfolio

Follow Susquehanna Fundamental Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email